- Home
- LDP vs FHTX Comparison
LDP vs FHTX Comparison
Compare LDP & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- FHTX
- Stock Information
- Founded
- LDP 2012
- FHTX 2015
- Country
- LDP United States
- FHTX United States
- Employees
- LDP N/A
- FHTX N/A
- Industry
- LDP Finance Companies
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- LDP Finance
- FHTX Health Care
- Exchange
- LDP Nasdaq
- FHTX Nasdaq
- Market Cap
- LDP 607.2M
- FHTX 513.7M
- IPO Year
- LDP N/A
- FHTX 2020
- Fundamental
- Price
- LDP $20.43
- FHTX $5.14
- Analyst Decision
- LDP
- FHTX Strong Buy
- Analyst Count
- LDP 0
- FHTX 5
- Target Price
- LDP N/A
- FHTX $13.80
- AVG Volume (30 Days)
- LDP 102.5K
- FHTX 197.3K
- Earning Date
- LDP 01-01-0001
- FHTX 11-04-2024
- Dividend Yield
- LDP 7.91%
- FHTX N/A
- EPS Growth
- LDP N/A
- FHTX N/A
- EPS
- LDP N/A
- FHTX N/A
- Revenue
- LDP N/A
- FHTX $25,515,000.00
- Revenue This Year
- LDP N/A
- FHTX N/A
- Revenue Next Year
- LDP N/A
- FHTX $11.54
- P/E Ratio
- LDP N/A
- FHTX N/A
- Revenue Growth
- LDP N/A
- FHTX N/A
- 52 Week Low
- LDP $16.16
- FHTX $2.70
- 52 Week High
- LDP $20.30
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- LDP 35.63
- FHTX 27.35
- Support Level
- LDP $20.12
- FHTX $4.69
- Resistance Level
- LDP $21.15
- FHTX $5.70
- Average True Range (ATR)
- LDP 0.28
- FHTX 0.61
- MACD
- LDP -0.09
- FHTX -0.14
- Stochastic Oscillator
- LDP 22.46
- FHTX 16.24
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.